| abstract |
Compound or a pharmaceutically acceptable salt, solvate of formula I, a polymorph, enantiomer, or racemic mixtures, wherein R1, R2 are each independently hydrogen, -OH, alkyl, -CF 3, -OCHF 2, be -OCF 3 or halogen; R3 is cycloalkyl, -OCH 2 CF 3, -OCH 2 CHF 2, -OCH 2 CH 2 F or -OCH 2 CH 3; R4 is hydrogen, -OH , -O aryl, -OCH 2 aryl, alkyl, cycloalkyl, -CF 3, -OCHF 2, -OCF 3, -OCH 2 CF 3, -OCH 2 CHF 2, be -OCH 2 CH 2 F, or halogen; A is —CX 1 X 2 , wherein X 1 and X 2 are each independently H, F and Cl, and when both X 1 and X 2 are H, R 3 is —OCH 2 CH 3 Is not a compound or Pharmaceutically acceptable salt, solvate, polymorph, discloses enantiomer, or racemic mixtures. This compound has the activity of an inhibitor of sodium-dependent glucose transport protein. Also disclosed are methods for preparing the compounds, pharmaceutical compositions containing the compounds, and the use of the compounds and pharmaceutical compositions thereof in the preparation of SGLT2 inhibitor drugs and the treatment of related diseases. [Chemical 1] |